Stocky turns companies like 4D Molecular Therapeutics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. FDMT scores 22/100 overall, with a Value Compounder Score of just 14/100 reflecting early-stage financial metrics. The company faces two medium-severity structural risks: FDA regulatory approval is mandatory before commercialization of its product candidates, and clinical trial enrollment capacity will determine development timelines. Leadership Alignment at 55/100 offers modest confidence. Until clinical progress materializes and regulatory pathways clarify, downside risks outweigh upsid
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for 4D Molecular Therapeutics, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 22/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates 4D Molecular Therapeutics, Inc. (FDMT) at 22/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. FDMT scores 22/100 overall, with a Value Compounder Score of just 14/100 reflecting early-stage financial metrics. The company faces two medium-severity structural risks: FDA regulatory approval is mandatory before commercialization
FDMT's current Stocky Verdict is 22/100, placing it in the "Avoid" band. This composite combines a 14/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for 4D Molecular Therapeutics, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
4D Molecular Therapeutics, Inc. scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
4D Molecular Therapeutics, Inc.'s Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to 4D Molecular Therapeutics, Inc..
Sign up free and unlock the full analysis on FDMT — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for FDMT in the app.
